TW200606177A - Glycoprotein VI antibodies and methods thereof - Google Patents

Glycoprotein VI antibodies and methods thereof

Info

Publication number
TW200606177A
TW200606177A TW094113726A TW94113726A TW200606177A TW 200606177 A TW200606177 A TW 200606177A TW 094113726 A TW094113726 A TW 094113726A TW 94113726 A TW94113726 A TW 94113726A TW 200606177 A TW200606177 A TW 200606177A
Authority
TW
Taiwan
Prior art keywords
antibodies
methods
glycoprotein
gpvi
agents
Prior art date
Application number
TW094113726A
Other languages
English (en)
Inventor
Narendra Nath Tandon
Yutaka Matsumoto
Hisao Takizawa
Keiji Okuyama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200606177A publication Critical patent/TW200606177A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094113726A 2004-04-29 2005-04-28 Glycoprotein VI antibodies and methods thereof TW200606177A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56617104P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
TW200606177A true TW200606177A (en) 2006-02-16

Family

ID=35149339

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094113726A TW200606177A (en) 2004-04-29 2005-04-28 Glycoprotein VI antibodies and methods thereof

Country Status (12)

Country Link
US (1) US7611707B2 (zh)
EP (1) EP1745076B1 (zh)
JP (1) JP2008507476A (zh)
KR (1) KR101194446B1 (zh)
CN (1) CN1964990B (zh)
AR (1) AR048638A1 (zh)
AU (1) AU2005243193B2 (zh)
CA (1) CA2565063A1 (zh)
ES (1) ES2389047T3 (zh)
RU (1) RU2407752C2 (zh)
TW (1) TW200606177A (zh)
WO (1) WO2005111083A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
CN101370831B (zh) * 2006-01-13 2013-06-19 Irm责任有限公司 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体
WO2007116779A1 (ja) 2006-03-31 2007-10-18 Mochida Pharmaceutical Co., Ltd. 新規血小板活性化マーカー及びその測定方法
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP2008249552A (ja) * 2007-03-30 2008-10-16 Otsuka Pharmaceut Co Ltd 可溶性血小板膜糖タンパク質ｖｉの測定系
US20100297116A1 (en) * 2007-10-31 2010-11-25 Yongge Liu Uses of a glycoprotein vi (gpvi) inhibitor
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
KR20120102125A (ko) * 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2402371A1 (en) * 2010-07-01 2012-01-04 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
WO2012032766A1 (ja) 2010-09-07 2012-03-15 持田製薬株式会社 血中可溶型ｇｐｖｉを用いたアルツハイマー病の診断方法
CN103396492A (zh) * 2013-08-06 2013-11-20 安徽新标志科技有限公司 抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用
WO2016168371A1 (en) * 2015-04-13 2016-10-20 Invitae Corporation Methods, systems and processes of identifying genetic variation in highly similar genes
BR112018002382A8 (pt) 2015-08-05 2022-12-06 Acticor Biotech Novos anticorpos anti-gvpi humano e usos dos mesmos
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
US11692033B2 (en) 2017-02-03 2023-07-04 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
US11542329B2 (en) 2018-05-16 2023-01-03 Morphosys Ag Antibodies targeting Glycoprotein VI
JP2022548646A (ja) 2019-09-16 2022-11-21 オプシディオ， エルエルシー 抗幹細胞因子抗体及びその使用方法
EP4229092A1 (en) * 2020-10-15 2023-08-23 Cornell University Therapeutic cemip antibodies
CN118043349A (zh) * 2021-06-11 2024-05-14 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK1177289T3 (da) * 1999-05-07 2008-08-11 Sanofi Aventis Deutschland Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
JPWO2003020306A1 (ja) * 2001-08-29 2004-12-16 伊東　恭悟 脱感作剤
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
US20070025992A1 (en) 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI

Also Published As

Publication number Publication date
KR20070010038A (ko) 2007-01-19
US7611707B2 (en) 2009-11-03
WO2005111083A2 (en) 2005-11-24
ES2389047T3 (es) 2012-10-22
CN1964990B (zh) 2012-12-12
AU2005243193A1 (en) 2005-11-24
KR101194446B1 (ko) 2012-10-24
AU2005243193B2 (en) 2011-01-27
JP2008507476A (ja) 2008-03-13
US20070202108A1 (en) 2007-08-30
CN1964990A (zh) 2007-05-16
CA2565063A1 (en) 2005-11-24
RU2006140407A (ru) 2008-05-27
EP1745076B1 (en) 2012-06-13
WO2005111083A3 (en) 2006-02-09
AR048638A1 (es) 2006-05-10
EP1745076A2 (en) 2007-01-24
RU2407752C2 (ru) 2010-12-27

Similar Documents

Publication Publication Date Title
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
IL245462A0 (en) Antagonists of human origin against cmet
TW200716646A (en) (S)-N-methylnaltrexone
TW200637522A (en) Skin treatment articles and methods
GEP20166454B (en) Sclerostin binding agents
TW200738270A (en) Method of treating depression using a TNFα antibody
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MY147217A (en) Antibody molecules having specificity for human il-06
UA85559C2 (en) Aminobenzophenone compounds
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
ATE433459T1 (de) Desoxo-nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
PL1713438T3 (pl) Mydło lecznicze
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
WO2004067718A3 (en) Necrosis-deficient mutants of tuberculosis bacteria
WO2003027320A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
EP1691836A4 (en) ANTI-PECAM TREATMENT FOR REMOVAL OF METASTASIS
WO2003006689A3 (en) Diagnosis and treatment of diseases associated with altered expression of hipk1
TW200628453A (en) Triazole substituted aminobenzophenone compounds
AU301438S (en) Hammock chair frame